Stockscreener 앱 받기
1.02
1.92%
-0.02
전일 마감가:
$1.04
열려 있는:
$1.06
하루 거래량:
65,035
Relative Volume:
0.41
시가총액:
$11.85M
수익:
-
순이익/손실:
$-10.93M
주가수익비율:
-0.7094
EPS:
-1.4378
순현금흐름:
$-10.72M
1주 성능:
+2.00%
1개월 성능:
-3.77%
6개월 성능:
-12.07%
1년 성능:
-58.28%
1일 변동 폭
$1.015
$1.06
1주일 범위
$0.9774
$1.1001
52주 변동 폭
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
명칭
Phio Pharmaceuticals Corp
전화
(508) 767-3861
주소
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.02 | 11.85M | 0 | -10.93M | -10.72M | -1.4378 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 재개 | H.C. Wainwright | Buy |
| 2020-08-05 | 개시 | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp 주식(PHIO)의 최신 뉴스
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
PHIO Q1 2026 Earnings: EPS Misses Estimates as Biotech Continues Clinical DevelopmentAnalyst Earnings Estimate - dars.gov.et
PHIO PE Ratio & Valuation, Is PHIO Overvalued - Intellectia AI
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock - Investing.com
Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock By Investing.com - Investing.com Nigeria
[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity - Stock Titan
Form 4 Phio Pharmaceuticals Corp For: 29 June By Investing.com - Investing.com South Africa
PHIO: PH-762 achieved strong safety and efficacy, with INTASYL poised for broader clinical impact - TradingView
PHIO: PH-762 achieved 85% response with no serious adverse events; next trial planned for early next year - TradingView
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026 - TMX Newsfile
PHIO PHARMACEUTICALS CORP (PHIO) Stock Chart - ChartMill
Phio CEO to pitch INTASYL cancer platform in June 30 webcast - Stock Titan
Phio Pharmaceuticals (PHIO) Life Sciences Virtual Investor Forum Summary - Quartr
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 - EIN News
PHIO Forecast — Price Target — Prediction for 2027 - TradingView
Phio Pharmaceuticals Corp. Actuals & Estimates (MUN:44R1) - TradingView
44R1 Forecast — Price Target — Prediction for 2027 - TradingView
Phio Pharmaceuticals begins commercial-scale production of PH-762 By Investing.com - Investing.com South Africa
Phio Pharmaceuticals begins commercial-scale production of PH-762 - Investing.com
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026 - The Des Moines Register
PHIO Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesOne-Time Loss Impact - dars.gov.et
PHIO Should I Buy - Intellectia AI
Phio CEO to pitch INTASYL cancer platform at investor forum June 25 - Stock Titan
Phio Pharmaceuticals Corp (PHIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Phio Pharmaceuticals Corp (PHIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Phio Pharmaceuticals Corp (PHIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Phio Pharmaceuticals Corp (PHIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Phio Pharmaceuticals Corp (PHIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Phio Pharmaceuticals Corp (PHIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Phio Pharmaceuticals Corp (PHIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Phio Pharmaceuticals Corp (PHIO) Institutional Confidence - TradingKey
PHIO Q1 2026 Earnings: EPS Miss Widens as Clinical-Stage Biotech Continues R&D InvestmentEarnings Sentiment Score - newsline.com
PHIO Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesDividend Earnings Report - newsline.com
PHIO Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Reports ResultsProfit Inflection Point - newsline.com
Number of shareholders of Phio Pharmaceuticals Corp. – MUN:44R1 - TradingView
Phio Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as R&D Spending IntensifiesEPS Growth Report - dars.gov.et
Phio Pharmaceuticals Slides 2.6% as Selling Pressure PersistsStock Analysis - dars.gov.et
Phio Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Biotech Reports No Revenue - The Legal Advocate
Phio Pharmaceuticals (PHIO) Edges Higher, Testing Key Resistance at $1.17Reversal Setup Alerts - newsline.com
PHIOPhio Pharmaceuticals Corp Short Interest - Finviz
Phio Pharmaceuticals Shares Tick Higher as CEO Hits the Road; Traders Eye Small Biotech - Bez Kabli
PHIO Q1 2026 Earnings: EPS Misses Estimates Amid Continued Clinical Trials FocusRevenue Beat Analysis - The Legal Advocate
Skin cancer treatment PH-762: Phio live Q&A session May 28 - Stock Titan
Phio Pharmaceuticals Holds Steady Near Support Levels; PHIO Stock Consolidates in Narrow RangeMA Cross Alert - The Legal Advocate
PHIO Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing R&D InvestmentInvestor Earnings Call - thelegaladvocate.com
Phio Pharmaceuticals Corp (PHIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):